Duration of intravenous antibiotic treatment for respiratory exacerbations in children with cystic fibrosis

Archives of Disease in Childhood

Volumn 95, Issue 7, 2010, Pages 568-

  Brown, Sarah M N ^a   Balfour Lynn, I M ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SEX DIFFERENCE; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS;

EID: 77953805526     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.185751     Document Type: Letter

References (4)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-904.
2. Elborn JS, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis - control and treatment of infection. J Cyst Fibros 2009;8:211-7.
3. Fernandes BN, Plummer A, Wilman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2008;16:CD006682.
4. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax 2005;60:517-20.